Basal Insulin in Vulnerable Patients with Type 2 Diabetes
Program Medium
Internet-based program
Estimated Time to Complete Educational Activity
2.5 hours
Course Overview
In this web-based program, physicians and optometrists will learn how recent developments have helped to advance the management of Type 2 diabetes
Release Date
July, 18, 2017
Expiration Date
July 18, 2019
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period July, 18, 2017 through July 18, 2019 participants must:
1) read the learning objectives and faculty disclosures;
2) study the educational activity, and are expected to view all 9 segments totaling 2.5 hours to successfully complete the activity and earn CME credit;
3) register and complete the evaluation form and post-test;
4) score 100% on the post-test; and
5) print out your CME certificate.
Registration
Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support
Supported by an educational grant from Sanofi Diabetes
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. ‘The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
University of Massachusetts Medical School requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to University of Massachusetts Medical School policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Other Credits
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCM.
Program Faculty and Disclosure
VIVIAN A. FONSECA, MD, FRCP
Program Chair
Professor of Medicine and Pharmacology
Tulis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA
Research Support (To Tulane): Grants from Asahi, Bayer
Consulting and Speaking: Takeda, Novo Nordisk, Sanofi-aventis, Eli Lilly, Astra-Zeneca, Janssen
JUAN P. FRIAS, MD, FACE
Clinical Assistant Professor of Medicine
University of California
President
National Research Institute
Los, Angeles, California
Consulting: Astra Zeneca, BMS, Johnson and Johnson, Novo Nordisk, Sanofi
Speaker’s Bureau: Sanofi, Eli Lilly, Novo Nordisk, Astra Zeneca
Contracted Research: AbbVie, AstraZeneca, Boehringer Ingelheim, BMS, Elcelyx, Eli Lilly, IONIS, Janssen, Johnson and Johnson, Ligand, Merck, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi, Theracos, vTv
GUILLERMO E. UMPIERREZ, MD, CDE
Professor of Medicine
Emory University School of Medicine
Physician
Emory University Hospital/Grady Health System
Atlanta, GA
Nothing to disclose
PABLO F. MORA, MD, MSc, FACE, CDE
Adjunct Associate Professor
University of Texas Southwestern Medical Center at Dallas
Staff Endocrinologist
Diabetes America (Plano)
Plano, Texas
Consultant and Speaker’s Bureau: Novo Nordisk
Educational Objectives
Upon completion of this activity, participants will be able to:
- Apply national guidelines, including the non-strictly algorithmic and flexibly prescriptive 2012 ADA/ EASD Guidelines focused on comprehensive management of diabetes; and identify therapeutic options, based on objective triggers—number and type of OADs, patient needs and preferences, target goal attainment, and other factors—consisting of oral, basal insulin-, and/or combined oral-insulin regimens that provide guideline-consistent care for this population.
- Explain the physiologic basis of long-acting insulin formulations and how mimicking physiologic insulin triggers and time-activity profiles may improve efficacy and safety of long-acting formulations;
- Identify patients with T2D who are not meeting target goals for HbA1 and/or other targets require initiation with or who require intensification with basal insulin therapy;
- Assess and calculate the risks of hypoglycemia in their patients with T2D, counsel their patients on recognizing symptoms of hypoglycemia, and select among therapeutic agents, including established and longer-acting basal insulin-based therapies and combination oral-insulin-based treatments that may reduce the risk of hypoglycemia in this patient subgroup;
- Understand how new basal insulin formulations in development or recently introduced into clinical use may help reduce the risk of hypoglycemia associated with insulin use;
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.
Privacy Policy
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
• We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
• You should check this privacy policy periodically to see whether we have made any changes